natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of any of claims 1 to 5, wherein R1, R2 are independently selected from C1-C6 alkyl, (C6-C10)aryl(C2-C6)alkenyl. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 5, gdje Ri, R> su nezavisno odabrani od Ci-Cg alkil, (C4-Cro)ari(C>-Cs)alkenil.
A pharmaceutical composition comprising the oligomeric compound of any one of claims 1-16, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant. 
Farmaceutski pripravak, naznačen time, da obuhvaća oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 16 1 farmaceutski prihvatljivo sredstvo za razrjeđivanje, nosač, sol ili adjuvant.
A flue gas purification device with a scrubber tower (10), which scrubber tower (10) comprises: 
Uređaj za pročišćavanje dimnih plinova, naznačen time, da ima toranj za ispiranje (10), gdje taj toranj za ispiranje
It was further cooled to −10 to −15° C. and stirred at the same temperature for 12 h. 
Nadalje je ohlađeno na -10 *C€ do -15 "C te miješano na istoj temperaturi tijekom 12 sati.
A compound for use of claim 2, wherein the condition is musculoskeletal fibrosis. 
Spoj za uporabu prema zahtjevu 2, jetrene fibroze i ačno fbroze.
5 of the indole then R9 does not exist; 
- kad je atom sumpora pričvršćen preko atoma br. 2 indola tada R' ne-postoji
Item 9. A salt according to item 1, 2 or 3, for use as a medicament for treating or preventing an AB-related pathology in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
Sol prema zahtjevu 1, 2 ili 3, naznačena time da je za uporabu kao lijek za liječenje ili sprječavanje AB-povezanih patologija u kombinaciji s barem jednim sredstvom za kognitivno poboljšanje, sredstvom za poboljšanje pamćenja, ili inhibitorom kolin esteraze.
A composition comprising a solid ligand-modified poly oxo-hydroxy metal ion material as defined in any one of claims 23 to 33 for use in therapy for delivery of the metal ion to the subject or for use the therapeutic removal or inhibition of an endogenous substance present in a subject that is capable of binding to the solid ligand-modified poly oxo-hydroxy metal ion material. 
Sastav koji sadrži kruti materijal poli-okso-hidroksi-metalnih iona modificiran ligandom, prema bilo kojem od zahtjeva 26 do 33, naznačen time, da se upotrebljava u liječenju isporukom metalnog iona za osobu ili je za uporabu za terapeutsko odstranjivanje ili inhibiciju endogene tvari koja je prisutna kod osobe, kada je ona osposobljena za vezanje na kruti materijal poli-okso-hidroksi-metalnih iona modificiran ligandom.
a binding domain capable of binding to the mucin domain having seq ID:440, the three EGF-like domains having seq ID:441 or the Sushi/SCR/CCP domain having seq ID:442 of the extracellular domain of TEM1; and 
vežuća domena, koja se može vezati na mucinsku domenu sa SEQ ID:440, tri EGF-u slične domene sa SEQ ID:441 ili Sushi/SCR/CCP domenu sa SEQ ID:442 izvanstanične domene TEM1; i
The combination of claim 8 wherein the formulation is suitable for administration by subcutaneous injection. A kit comprising: 
Kombinacija prema patentnom zahtjevu 8 naznačena time što je formulacija pogodna za primjenu potkožnom injekcijom.
ppm polysorbate 80 in combination with 10 mM methionine or 80 ppm polysorbate 80 in combination with 5 mM methionine, 
ppm polisorbata 80 u kombinaciji s 10 mM metioninom ili 80 ppm polisorbata 80 u kombinaciji s 5 mM metioninom,
A compound having the structure or a pharmaceutically acceptable salt thereof, for use in a method of reducing Ghrelin level in the gastrointestinal tract. 
OH b s ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku reduciranja razine Grelina u gastrointestinalnom traktu.
at each occurrence is independently selected from H, F, C1-C6 alkyl, and C1-C6 alkoxy; and x is 0, 1,2, 3, or 4; provided, 
je u svakom pojavljivanju nezavisno odabran od H, F, C1-C6 alkil i C1-C6 alkoksi; i x je 0, 1, 2, 3 ili 4; pod uvjetom da
to give a tricyclic indazole compound of general formula (I). 
MePhSO:-), za dobivanje tricikličkog spoja indazola opće formule (1).
A number of such intermediates are: 
Broj objave europskog patenta:
Alternatively the reaction may be carried out in one of the above inert solvents conveniently in the presence of a base, for example potassium carbonate. 
Alternativno se reakcija može provesti u jednom od gornjih inertnih otapala poželjno u prisutnosti baze, primjerice kalij-karbonata.
Radiotherapy; and Other therapeutic or prophylactic agents. 
Radioterapija; i n. - Druga terapijska 1 profilaktička sredstva.
The crude product is dissolved in DCM, and PS-trisamine (2 eq) and PS-isocyanate (1 eq) are added. 
Sirovi produkt otopi se u DCM-u, te se doda PS-trisamin (2 ekv.) i PS-izocijanat (1 ekv.).
The present invention provides a compound of formula (I) wherein M is H. 
Spoj sukladno patentnom zahtjevu 1, naznačeno time, što M je H.
The objective of the invention is to offer several improvements with respect to the state of the art. One of those improvements is to provide a continuous and efficient slow release of the active substance during at least a period covering the 6th month after injection of the composition. To this effect the invention concerns a pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: 
Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži prvu skupinu mikročestica 1 drugu skupinu mikročestica, gdje a) mikročestice te prve skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi; taj kopolimer obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.5 i 0.9 dl/g, kako je mjereno u kloroformu na 25*C i pri koncentraciji polimera od 0.5 g/dL; b) mikročestice te druge skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi i koji obuhvaća količinu mliječne kiseline između 70% i 80% (molarno); mikročestice te prve i druge skupine dalje imaju raspodjelu čestica definiranu kako slijedi:
The use according to claim 34, wherein said whole antibody or antibody fragment is a human, humanized, chimerized or deimmunized antibody or antibody fragment. 
Uporaba prema zahtjevu 34, naznačena time, što je spomenuto cijelo antitijelo ili dio antitijela humano, humanizirano, himerizirano ili deimunizirano antitijelo ili dio antitijela.
The compactin sample (30 g) was suspended in acetonitrile (5 times by volume) and heated to reflux. 
Uzorak kompaktina (30 g) je suspendiran u acetonitrilu (u 5 puta većem volumenu) i zagrijan do refluksa.
The composition according to claim 1, comprising 9% to 13% (wt/wt) magnesium and about 8% to 12% (wt/wt) potassium on a dry basis, having a bulk density of 0.55 to 0.65 g/cm3. 
Sastav usklađen s patentnim zahtjevom 1 obuhvaća 9% do 13 % (wt/'wt) magnezija 1 8% do 12% (wt/wt) kalija u suhoj osnovi, ima ukupnu gustoću od 0,55 do 0,65 g/cm3.
In one aspect, the non-human portion of a chimeric human/non-human MHC II B polypeptide comprises transmembrane and cytoplasmic domains of an endogenous non-human MHC II B polypeptide. In one embodiment, the human portions of a chimeric human/mouse MHC II a and B polypeptides are derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
Životinja prema zahtjevu 8, naznačena time, da se humani dio kimernog ljudskog/mišjeg MHC-II-a-polipeptida kodira putem humanog gena HLA razreda II odabranog iz skupine koja se sastoji od bilo kojeg gena a-lanca od HLA-DR, HLA-DQ i HLA-DP; te time, da se humani dio kimernog ljudskog/mišjeg MHC-II-fB-polipeptida kodira putem humanog gena HLA razreda II odabranog iz skupine koja se sastoji od bilo kojeg gena B-lanca od HLA-DR, HLA-DQ i HLA-DP.
The method of claim 7, wherein said ivermectin is in a concentration range from about 0.05% to about 3.0% (w/w). 
Uporaba prema jednom od zahtjeva 1 do 3, naznačena time da je navedeni spoj avermektina u koncentraciji u rasponu od oko 0.05% do oko 3.0% (tež./tež.).
A process according to claim 14 or 15, wherein the isolated polypeptide with esterase activity comprises the amino acid sequence shown in SEQ ID No. 
Postupak prema zahtjevu 14 ili 15, naznačen time da izolirani polipeptid s aktivnošću esteraze sadrži sekvencu amino kiseline prikazanu u SEQ ID No.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 1, wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje je anti-CTLA-4 antitijelo odabrano iz grupe koja se sastoji od ipilimumaba i tremelimumaba.
The method of claim 2, wherein: the first column comprises M-2 blanks, and 
Metoda iz patentnog zahtjeva 2, gdje:
a fuel gas supply line (L1) configured to extract LNG from the LNG tank and supply the extracted LNG as fuel gas to the high-pressure gas injection engine; 
vod za dobavu pogonskog plina spojen iz spremnika LNG (1) do visokotlačnog plinskog injekcijskog motora za brod;
wherein said high molecular weight polyethylene oxide is in an amount of at least 54%, by weight, based upon the total weight of said tablet-shaped pharmaceutical preparation, not including the combined weight of said applied coatings. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevu 12, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem 1,000,000.
The films according to claim 46, characterised in that they are selected from the group comprising stretched and/or oriented films, and preferably breathable films, or extrusion coating films. 
Filmovi prema zahtjevu 22, naznačeni time da su odabrani iz skupine koja sadrži razvučene i/ili orijentirane filmove, te poželjno prozračne filmove, ili filmove ekstruzijskih prevlaka.
B-vinyl-16B-fluoro-estra-1,3,5(10)-triene-B,17B-diol Pharmaceutical compositions that contain at least a compound according to one of claims 1 to 9 as well as a pharmaceutically compatible vehicle. 
Farmaceutski pripravci naznačeni time da sadrže barem spoj prema jednom od zahtjeva 1 do 7 kao i farmaceutski kompatibilan nosač.
It may reportedly be prepared according to the procedures set forth in U.S. Patent No. 
Može se pripraviti prema postupcima izloženim u US patentu br.
Thyroid peroxidise, or a fragment thereof, for use as part of a method as recited in claim 20, wherein said immune-mediated disease is selected from the group consisting of graft versus host disease, rheumatoid arthritis, vasculitis, organ transplant rejection, uveitis, scleroderma, autoimmune cytopenia, and multiple sclerosis. 
Anti-CD52 protutijelo za uporabu prema bilo kojem od zahtjeva 18 do 22, naznačeno time da pacijent ima imunološki posredovanu bolest odabranu iz skupine koju čine bolest transplantata protiv primatelja, reumatoidni artritis, vaskulitis, odbacivanje presađenog organa, uveitis, skleroderma i autoimuna citopenija.
For example, as shown in FIG. 22, 2′-O-TBDMS-9,10-a,a-OH, 9 desoxo, 10 deacetyl paclitaxel of Formula 8 (where R1═R2═Ph; P1=TBDMS in generalized formula H of Scheme 4) may be mono-acylated on the 7-hydroxyl as Formula 12 (corresponding to generalized formula J of Scheme 4), bis-acylated on the 7,10-hydroxyls as Formula 13 (corresponding to generalized formula J′ of Scheme 4), and/or tris-acylated on the 7,9,10-hydroxyls as Formula 14 (corresponding to generalized formula J″ of Scheme 4). 
Na primjer, kao što je prikazano na slici 22, 2'-O-TBDMS-9,10-a,a-OH, 9-dezokso, 10 deacetil paklitaksela formule 8 (gdje R;=R,=Ph; P,=TBDMS u općoj formuli H iz sheme 4) može biti mono-aciliran na 7-hidroksilu kao formula 12 (što odgovara općoj formuli J iz sheme 4), bi-aciliran na 7,10-hidroksilnim skupinama kao formula 13 (što odgovara općoj formuli J' iz sheme 4), i/ili tri-aciliran na 7,9,10-hidroksilnim skupinama kao formula 14 (što odgovara općoj formuli J" iz sheme 4).
A combination of at least one sigma ligand and at least an opioid or opiate compound for simultaneous, separate or sequential administration for use in potentiating the analgesic effect of opioids or opiates and for decreasing the dependency induced thereby. 
Sastav od barem jednog sigma liganda i barem opioidnog ili opijatnog spoja za istovremenu, odvojenu ili serijsku administraciju za uporabu u potenciranju analgetičkog efekta opioida 1li opijata i za smanjenje njima uzrokovane ovisnosti.
A binding molecule according to claim 6, wherein said influenza infection is caused by an influenza virus that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 5, naznačeni time da je navedena infekcija influence uzrokovana sa virusom influence koji se povezuje sa izbijanjem pandemije, ili ima potencijal da se poveže sa izbijanjem pandemije.
the ceftriaxone or the pharmaceutically acceptable salt thereof, is present in an amount of about 0.125 g, calculated as ceftriaxone free acid, 
(a) spomenuti ceftriakson natrij u količini od 0.125 g, preračunato kao ceftriaksonska slobodna kiselina,
The product of claim 1, wherein the coffee is derived from roasted arabica, robusta, or any combination of beans, ground and instant powder. 
Proizvod u skladu s patentnim zahtjevom 1, naznačen time što se kavu dobiva prženjem zrna C. arahica, C. robusta, ili bilo koje kombinacije zrna, mljevenog praha i praha za instant kavu.
The panel according to any claims 1 to 7 characterized in that it comprises attachable system as means for attaching of line elements (3) on cover (5) of modular sandwich panel (1). 
Panel prema bilo kojem od zahtjeva 1 do 7, naznačen time što sadrži pričvrsni sistem kao sredstvo za pričvršćivanje linijski izvedenih elemenata (3) na vanjski pokrivač (5) modularnog sendvič panela (1).
A method of treating a subject suffering from a condition associated with vasopressin receptor activity, which comprises administering to the subject a therapeutically effective amount of the compound of Formula I as defined in claim 1, wherein said condition is selected from inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, diabetic nephropathy, hyponatremia, cerebral edema, cerebral ischemia, stroke, thrombosis, water retention, aggression, obsessive-compulsive disorders, dysmenorrhea, nephrotic syndrome, anxiety and central nervous injuries. 
Spoj Formule I, kao što je definirano u Zahtjevu 1, za upotrebu u liječenju osobe koja boluje od stanja povezanog s aktivnošću receptora za vazopresin, naznačen time, da je spomenuto stanje izabrano od poremećaja unutarnjeg uha, hipertenzije, kongestivnog zatajenja srca, srčane insuficijencije, koronarnog vazospazma, srčane ishemije, jetrene ciroze, bubrežnog vazospazma, zatajenja bubrega, dijabetesne nefropatije, hiponatrijemije, cerebralnog edema, cerebralne ishemije, kapi, tromboze, zadržavanja vode, agresije, opsesivno-kompulsivnih poremećaja, dismenoreje, nefrotičkog sindroma, anksioznosti i ozljeda središnjeg živčanog sustava.
obtaining (2530) a context offset used in entropy decoding of the first critical value flag for a current significant coefficient based on the number of previous transformation coefficients having consecutive 1s included in a current subset when the current significant coefficient is not initially entropy-decoded in the current subset and the previous transformation coefficients having consecutive 1s are decoded before the current significant coefficient, according to a scan order of the current subset; and 
pribavljanje (2530) kontekstnog pomaka upotrebljavanog u entropijskom dekodiranju indikatora prve kritične vrijednosti na osnovi broja prethodnih koeficijenata transformacije sa slijedećom ls; te pribavljanje (2540) indeksa konteksta koji označava kontekst upotrebljavan u entropijskom dekodiranju indikatora prve kritične vrijednosti upotrebom indeksa skupa konteksta i kontekstnog pomaka,
The solid pharmaceutical formulation of any one of claims 1 to 5 wherein the pre-gelatinized starch is pre-gelatinized corn starch. 
Kruta farmaceutska formulacija prema bilo kojem zahtjevu od 1 do 5 naznačena time da pre-želatinizirani škrob je pre-želatinizirani kukuruzni škrob.
The compound or salt for use according to claim 23, wherein said cancer is lymphoma. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak limfom.
preparing sample solutions of the amino acid components of glatiramer acetate and of bromotyrosine; 
pripremanje otopina uzoraka aminokiselinskih komponenata glatiramer acetata i bromtirozina;
alkoxyalkyl; Z is selected from the group consisting of -NR5- and -O-; R4 is selected from the group consisting of: 
R'* je odabran iz grupe koja se sastoji od: a) b) c) d) vodika; alkila; aralkila;
The method as disclosed above, which form the subject of the present invention, may be obviously used not only for preparing adipose tissue to be transplanted, but also for preparing any type of cell agglomerate that is required to have a high purity level for use. method of preparing adipose tissue for transplantation, from lobular fat extracted, for instance, by liposuction, said fat consisting of a fluid component comprising an oily component, a blood component and/or sterile solutions and of a solid component comprising cell fragments, cells and one or more cell macroagglomerates of heterogeneous size, characterized in that it includes the steps of: 
HR P20180957 T1 PATENTNI ZAHTJEVI Metoda pripremanja adipoznog tkiva za transplantaciju, iz lobularne masti koja je izvučena, na primjer, pomoću liposukcije pri čemu se navedena mast sastoji od fluidne komponente koja sadrži uljanu komponentu, komponentu krvi i/ili sterilne otopine 1 od čvrste komponente koja sadrži fragmente stanica, stanice i jedan ili više staničnih makroaglomerata heterogene veličine, naznačena time da uključuje najmanje jedan korak ispiranja staničnih agregata koji je izveden u isto vrijeme kao 1 korak odvajanja fluidne komponente, u obliku emulzije, od čvrste komponente; navedeni korak ispiranja 1 odvajanja se odvija pomoću:
Ig-like domain containing proteins can be captured from a biological fluid or cell lysate using a HCIC resin such as MEP HYPERCEL®. 
Proteini koji sadržavaju Ig-slične domene mogu se iz biološke tekućine ili staničnog lizata uhvatiti pomoću smole za HCIC, primjerice MEP HyperCel.
After one hour stirring at room temperature, sodium cyanoborohydride (0.78 g, 0.0124 mole) is added and the mixture is stirred for 18 h at room temperature. 
Nakon 1 sata miješanja na sobnoj temperaturi doda se natrijev cijanoborohidrid (0,78 g, 0,0124 mol), a smjesu miješa 18 sati na sobnoj temperaturi.
reducing a cyano moiety of a compound of Formula 6, or a salt thereof, to yield a compound of Formula 7, or a salt thereof; 
(b) dekarboksiliranju spoja Formule 7, ili njegove soli, kako bi se dobilo spoj Formule I, ili njegovu sol; i
Consequently, the combinations of the invention possess therapeutically advantageous properties, which make them particularly suitable for the treatment of respiratory diseases in all kind of patients. 
Prema tome, kombinacije sukladno predmetnom izumu posjeduju terapijski povoljne osobine, koje ih čine osobito prikladnim za liječenje respiratornih bolesti kod svih vrsta bolesnika.
The method of claim 9, wherein the ALF information comprises filter coefficients, and filter shape, filter selection index, filter classification method, and filter on/off control flag. 
Postupak prema patentnom zahtjevu 4, pri čemu ALF podatak sadrži koeficijente filtera, i oblik filtera, indeks selekcije filtera, postupak klasifikacije fitlera, i oznaku upravljanja uklj/isklj filtera.
glycopyrronium bromide at a dosage in the range from 5 to 26 µg per actuation; 
(a) < glikopironijev bromid u dozi u rasponu od 5 do 26 ug po aktiviranju;
The FGF-21 polypeptide of claim 19, wherein the non-naturally encoded amino acid comprises a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group. 
FGF-21 polipeptid prema zahtjevu 19, gdje aminokiselina koja nije prirodno kodirana sadrži karbonilnu skupinu, aminooksi, hidrazid, hidrazin, semikarbazid, azid ili alkin.
A pharmaceutical composition comprising a compound of any one of embodiments 1 to 37, or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži spoj prema jednom od zahtjeva 1 do 18 ili njegovu farmaceutski prihvatljivu sol.
A container according to any of the preceding claims, wherein the adhesive label is partially permanently affixed to the inner package. 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je naljepnica (608) djelomično trajno pričvršćena na unutrašnje pakiranje (606).
identifying at least one cell comprising in its genome the insert polynucleotide integrated at the target genomic locus, wherein integration of the insert polynucleotide introduces a genetic modification comprising deletion of an endogenous nucleic acid sequence and replacement with an exogenous nucleic acid sequence at the target genomic locus, wherein the cell is not produced using a process which involves modifying the germ line genetic identity of human beings or which involves use of a human embryo for industrial or commercial purposes, and wherein the method is not a method for treatment of the human or animal body by therapy. 
identificiranje barem jedne stanice koja sadrži u svom genomu umetnuti polinukleotid integriran u ciljanom genomskom lokusu, pri čemu integracija umetka polinukleotida uvodi genetsku modifikaciju koja sadrži deleciju endogene sekvence nukleinske kiseline i zamjenu s eksogenom sekvencom nukleinske kiseline na ciljanom genomskom lokusu, pri čemu stanica ne proizvodi pomoću postupka koji uključuje modificiranje genetskog identiteta klicine linije ljudskih bića ili koji uključuje uporabu ljudskog embrija u industrijske ili komercijalne svrhe, i pri čemu postupak nije postupak liječenja čovjeka ili životinje terapijom.
The carrier of any of claims 1 to 3, wherein the molecular sieve consists in sodium alumino silicate. 
Nosač prema zahtjevu 6, gdje se molekularno sito sastoji od natrijevog aluminosilikata.
R is selected from H, a hydroxyl group, alkyl C1-C4, alkenyl C1-C3, cycloalkyl C3-C7 or any substituted or unsubstituted aryl group; 
R se bira između H, hidroksilne skupine, alkila C,-C,, alkenila C;-C:, cikloalkila Cs-C; ili bilo koje supstituirane ili nesupstituirane arilne skupine;
A method as claimed in claim 6, wherein the zofenopril calcium form A is substantially free of other forms of zofenopril calcium. 
Postupak prema patentnom zahtjevu 6, gdje je zofenopril kalcij oblik A u značajnom stupnju oslobođen drugih oblika zofenopril kalcija.
Lyophilization process was performed as before for Formulations ET-NF A, ET-NF B and ET-NF F (Table IX). 
Proces liofilizacije je izveden kao u prethodnom slučaju za oblike ET-NF A, ET-NF B i ET-NF F (Tablica IX).